

### **AMENDMENTS TO THE CLAIMS**

This listing of claims replaces all prior versions and listings of claims in the application.

#### **Listing of Claims:**

1. (Currently Amended) A therapeutic agent comprising
  - (a) a first domain that binds a first protein, the first protein having at least seven consecutive glutamine residues;
  - (b) a second domain that binds a second protein, the second protein having at least seven consecutive glutamine residues; and
  - (c) a third domain that separates the first domain from the second domain, wherein the therapeutic agent prevents interaction between the first protein and the second protein.
- 2-17. (Canceled)
18. (New) The therapeutic agent of claim 1, wherein the first domain and/or the second domain comprises a polypeptide.
19. (New) The therapeutic agent of claim 18, wherein the polypeptide comprises 3, 7, 10, 20, 30, 37, 38, 39, 40, 50, 75, 100, 150, 200, 250, or 300 consecutive glutamine residues and, optionally, a sufficient number of hydrophilic amino acid residues to increase the solubility of the therapeutic agent, the hydrophilic amino acid residues including at least one aspartic acid residue or glutamic acid residue.
20. (New) The therapeutic agent of claim 18, wherein the polypeptide consists of 3, 7, 10, 20, 30, 37, 38, 39, 40, 50, 75, 100, 150, 200, 250, or 300 consecutive glutamine residues.
21. (New) The therapeutic agent of claim 18, wherein the polypeptide comprises at least 80% glutamine residues.

22. (New) The therapeutic agent of claim 21, wherein the polypeptide comprises at least 85%, 90%, 95%, or 98% glutamine residues.

23. (New) The therapeutic agent of claim 1, wherein the first domain and/or the second domain comprises a polypeptide comprising the first 17 amino acid residues of the huntingtin protein fused to 25 consecutive glutamine residues and, optionally, a sufficient number of hydrophilic amino acid residues to increase the solubility of the therapeutic agent, the hydrophilic amino acid residues including at least one aspartic acid residue or glutamic acid residue.

24. (New) The therapeutic agent of claim 1, wherein the first and second domains are identical.

25. (New) The therapeutic agent of claim 19, wherein the first and second domains are identical.

26. (New) The therapeutic agent of claim 21, wherein the first and second domains are identical.

27. (New) The therapeutic agent of claim 23, wherein the first and second domains are identical.

28. (New) The therapeutic agent of claim 1, wherein the third domain comprises a polypeptide or other physiologically acceptable polymer.

29. (New) The therapeutic agent of claim 28, wherein the third domain consists of a polypeptide comprising an alpha-helical region or a beta-sheet.

30. (New) The therapeutic agent of claim 28, wherein the third domain consists of a polypeptide comprising the sequence of a tata-binding protein or a fragment thereof and, optionally, a sufficient number of hydrophilic amino acid residues to increase the solubility of the therapeutic agent, the hydrophilic amino acid residues including at least one aspartic acid residue or glutamic acid residue.

31. (New) The therapeutic agent of claim 30, wherein the tata-binding protein consists of the sequence of SEQ ID NO:12.

32. (New) The therapeutic agent of claim 30, wherein the fragment of the tata-binding protein consists of the alpha-helical region H1 (SEQ ID NO:2), the alpha-helical region H2 (SEQ ID NO:3), the alpha-helical region H3 (SEQ ID NO:4), or the alpha-helical region H4 (SEQ ID NO:5), a fusion of H1/H2 (SEQ ID NO:6), a fusion of H2/H3 (SEQ ID NO:7), or a fusion of H3/H4 (SEQ ID NO:8).

33. (New) The therapeutic agent of claim 30, wherein the third domain consists of a polypeptide comprising SEQ ID NO:11.

34. (New) The therapeutic agent of claim 1, wherein the first, second, and third domains are polypeptides.

35. (New) The therapeutic agent of claim 1, wherein the first and/or second protein comprises 7, 10, 15, 20, 25, 30, 35, 36, 37, 38, 39, or 40 consecutive glutamine residues.

36. (New) The therapeutic agent of claim 35, wherein the first and/or second protein is huntingtin.

37. (New) The therapeutic agent of claim 35, wherein the first and/or second protein is an amyloid-associated protein.

38. (New) The therapeutic agent of claim 35, wherein the first and/or second protein is a transcription factor.

39. (New) The therapeutic agent of claim 1, wherein the first protein and the second protein are identical.

40. (New) The therapeutic agent of claim 1, wherein the interaction is aggregation.

41. (New) The therapeutic agent of claim 40, wherein the aggregation between a population of proteins consisting of the first protein and a population of proteins consisting of the second protein is inhibited by at least 25%.

42. (New) The therapeutic agent of claim 40, wherein the aggregation is inhibited by at least 30%, 40%, 50%, 60%, 70%, 80%, or 90%.

43. (New) The therapeutic agent of claim 1, wherein the interaction is dimerization.

44. (New) A pharmaceutically acceptable composition comprising the therapeutic agent of claim 1.